Despite concerns about cancer-causing agents in Ranitidine and an expert panel's recommendation to suspend it, India's drug advisory body has decided to form another committee to investigate. Previous tests revealed that many Ranitidine samples contained unsafe levels of NDMA impurities. The ICMR has been asked to conduct a study to assess the drug's...
BDR Pharmaceuticals plans $100 mn expansion in the US with manufacturing buyouts
BDR Pharmaceuticals is set to broaden its presence in the US through acquisitions of manufacturing facilities, backed by a $100 million investment. Chairman Dharmesh Shah mentioned the company is evaluating potential units and expects a decision within months, funded by internal accruals.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cK9xTlR
via...
Aster DM Healthcare completes acquisition of 5% stake in Quality Care India through share swap
Aster DM Healthcare has finalized the acquisition of a 5% stake in Quality Care India Ltd (QCIL) through a share swap with BCP Asia II TopCo IV Pte Ltd and Centella Mauritius Holdings Limited. This acquisition marks the initial phase of the strategic merger between Aster DM Healthcare and Quality Care India.
from Healthcare/Biotech-Industry-Economic...
Zydus Lifesciences gets USFDA nod for generic cholesterol lowering drug
Zydus Lifesciences Ltd. has secured final USFDA approval to manufacture generic Niacin extended-release tablets in 500 mg, 750 mg, and 1,000 mg strengths. These tablets, produced in Ahmedabad, address elevated cholesterol and triglycerides, reducing the risk of myocardial infarction. The US market for these tablets has annual sales of USD 5.5 million,...
Max Healthcare lines up Rs 6,000 crore for expansion
Max Healthcare is set to invest ₹6,000 crore over the next three years to expand its network, aiming to reach 25 hospitals by 2025. The expansion includes new facilities in Saket, Nanavati, Mohali, and Gurugram, with a recent inauguration of a 300-bed hospital in Dwarka.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pnvJMtA
via I...
Max Healthcare Institute to invest Rs 6,000 cr to add 3,700 beds by 2028
Max Healthcare will invest Rs 6,000 crore by 2028 to add 3,700 beds across India, increasing its facilities to around 30 hospitals. The expansion, funded internally, includes the recent inauguration of a 300-bed hospital in Dwarka, Delhi, and upcoming facilities in Mohali, Mumbai, and Saket. The company remains open to acquisitions beyond its organic...
Medanta to invest Rs 500 cr to set up 400-bed hospital in Guwahati
Global Health, known for its Medanta hospitals, is set to invest approximately Rs 500 crore in establishing a 400-bed super speciality hospital in Guwahati, Assam. The board has approved the land purchase for Rs 30 crore. This initiative aims to enhance healthcare infrastructure, offering advanced medical care across 20 specialities to over 50 million...
Dr Reddy's to introduce Sanofi's novel drug in India
Dr. Reddy's Laboratories has expanded its partnership with Sanofi Healthcare to introduce Beyfortus, a novel drug preventing lower respiratory tract disease in newborns caused by RSV. Dr. Reddy's will exclusively promote and distribute Beyfortus in India, with a launch expected in the second quarter of the current fiscal year, following regulatory...
Roche made over 100 times the cost of a medicine that it sold in India, calculations show; company defends itself
A recent report in The Times of India reveals that Roche may have profited immensely from risdiplam, a drug for spinal muscular atrophy (SMA), potentially earning 115 times its clinical trial expenses. Knowledge Ecology International estimates trial costs at $50 million, while Roche's risdiplam revenue reached $5.8 billion. Roche defends its pricing,...
Get evergreening patent requests very often, these benefit select few cos: Piyush Goyal
Piyush Goyal stated that India frequently receives requests to extend pharmaceutical patents for minor modifications. He criticized this practice, known as 'evergreening,' for prioritizing corporate profits over global healthcare access. Goyal highlighted Ayushman Bharat scheme, providing free healthcare to over 620 million people. He emphasized India's...
Zydus gets 6 observations from USFDA for API unit
Zydus Lifesciences on Saturday said the US health regulator has issued six observations after inspecting its Gujarat-based API manufacturing unit. "We wish to inform that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the group's API (active pharmaceutical ingredient) unit located at Dabhasa in Gujarat," the drug...
SS Innovations International to list on US exchange Nasdaq
SS Innovations International, an Indian surgical robotics company, is set to list on the Nasdaq under the ticker 'SSII' on April 25. The company experienced substantial revenue growth, reaching $20.6 million in 2024, a 3.5-fold increase from the previous year.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MAwe3r7
via IFT...
Reckitt Benckiser's rare reflection: India a big growth driver
Reckitt Benckiser's CEO, Kris Licht, highlights India as a key growth driver, anticipating sustained strong volume growth alongside China. The company's success is fueled by strong organic performance in germ protection (Dettol) and intimate wellness (Durex). Reckitt's strategic alignment with India's public health goals, through initiatives like 'Dettol...
To speed up delivery, govt exempts orphan drugs from testing at ports
To ensure timely access to life-saving orphan drugs for patients, the government has exempted mandatory sampling and testing at port offices. The drug regulator will now release consignments based on a legal undertaking from the importer. This decision addresses challenges like small volumes and specialized testing needs, streamlining the process and...
Relief for pharma cos as Delhi HC says cough syrup ban applies prospectively
The Delhi High Court has provided relief to pharma companies like Glenmark Pharmaceuticals and Zuventus Healthcare, ruling that the ban on fixed-dose combinations for children under four will be applied prospectively. The court directed companies to issue advisories to doctors and publish notices in national newspapers, informing that the drugs should...
Delhi HC orders cough syrup makers to warn against use in children below 4, issue public notices
Glenmark and Zuventus Healthcare have approached the Delhi High Court against the Centre’s April 15 notification banning the use of certain cough syrups for children below four years of age. The companies argued that the order should not apply retrospectively.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7BHbMS1
via IFT...
Drugs panel considering proposal to rein in sale of OTC medicines to prevent misuse
India's drug advisory board is considering restricting over-the-counter medication sales to prevent misuse and ensure patient safety. The proposal limits OTC sales to 27 drugs, including antipyretics and painkillers, with dosage and quantity restrictions. The board aims to increase accessibility while ensuring patient safety by excluding several currently...
Aurobindo Pharma arm gets USFDA nod for generic blood cancer drug
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd, has secured USFDA approval to produce and sell generic Dasatinib tablets, used for treating specific bone marrow and blood cancers. The approved tablets, available in multiple strengths, are therapeutically equivalent to Bristol-Myers Squibb's Sprycel. Launch is anticipated in Q1FY26, targeting...
Pharma & healthcare deals see shifting focus on scalable, global models: Grant Thornton Bharat
India's pharma and healthcare sector demonstrates resilient investor interest, marked by a 34% year-on-year increase in deal volumes and a 326% surge in values for Q1 2025. Despite a slight quarterly dip due to macroeconomic factors, high-value deals are on the rise, particularly in M&A and PE activity, signaling confidence in scalable models and...
Novo Nordisk to phase out key drug, insulin cos spot big biz opportunity
Novo Nordisk is set to discontinue some forms of its Mixtard insulin, including pen and cartridge versions, in India, coinciding with the anticipated launch of its weight-loss drug Wegovy. This move has prompted other major insulin manufacturers like Lupin, Eris, and Eli Lilly to increase their production capabilities to address the potential supply...
Dr Reddy's, Lupin recall products in US due to labelling, manufacturing errors: USFDA
Dr. Reddy's Laboratories and Lupin are recalling products in the US due to labeling and manufacturing issues. Dr. Reddy's is recalling an antiepileptic drug due to a labeling mix-up, where infusion bags were incorrectly labeled. Lupin Pharmaceuticals is recalling an antidepressant medication due to failed impurity specifications. The USFDA has classified...
India faces a silent cervical cancer crisis: Every 8 minutes, a woman dies, but HPV vaccine and early screening could prevent it
The National Academy of Medical Sciences (NAMS) has recommended categorising cancer as a notifiable disease to improve prevention and treatment in India. The organisation emphasised the importance of indigenous HPV tests and vaccines in cancer screening, alongside strengthening diagnostic infrastructure. Key recommendations include early detection,...
Novo Nordisk to discontinue Human Mixtard, India's largest selling insulin brand
Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global strategy. They will prioritize newer, patented therapies like Ozempic and Wegovy. The company plans to introduce these therapies in India this year. While vials will still be available, pen devices, preferred by many, may become...
Russia-Ukraine war: Indian pharma firm caught in crossfire, lobby seeks PM Modi’s help
An Indian pharmaceutical company, Kusum Healthcare, operating in Ukraine, suffered significant damages after a warehouse was reportedly struck by a missile, prompting the Federation of Pharma Entrepreneurs to seek Prime Minister Modi's intervention.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kKe1D3p
via IFT...
Shivinder Mohan Singh moves NCLT, files plea for personal insolvency
Shivinder Mohan Singh, the former Fortis Healthcare promoter, has sought personal insolvency before the NCLT, citing liabilities exceeding assets. Facing a Rs 3,500 crore recovery to Daiichi Sankyo, Singh's assets are largely attached or devalued due to litigation and mismanagement within RHC Holding.
from Healthcare/Biotech-Industry-Economic Times...
Pharmacists seek clarity on banned cough syrup stock
Pharmacists are seeking clarification from the DCGI regarding the handling of recently banned cough syrups for children under four, specifically concerning existing stocks and prescriptions. The IPA has requested guidance on whether to return stocks or sell them until depleted, and if prescriptions for young children can be dispensed. The industry...
Centre pushes for 'one nation, one swap transplant' system to boost kidney donations
India is set to promote kidney swap transplants nationwide, aiming to increase transplant numbers by up to 15%. Following a directive from NOTTO, states and union territories are encouraged to implement swap transplants, a practice already recognized but underutilized. The initiative includes a standardized document list and the potential creation...
Yoga vs Strengthening exercises: Which is better for knee osteoarthritis? Study reveals surprising results
A recent study indicates yoga is as effective as strengthening exercises for managing knee osteoarthritis, offering improvements in pain, quality of life, and depression. Experts highlight yoga's comprehensive approach, addressing mental health, balance, and joint mobility. Both yoga and resistance training achieve similar physiological goals through...
US tariff chaos, global headwinds hit pharma GCC hiring in India
Uncertainty surrounding US tariffs and global economic headwinds has tempered hiring in India's pharmaceutical and healthcare GCCs. Experts predict a 6-7% reduction in net talent addition this fiscal year as companies adopt a cautious approach. Despite this temporary slowdown, India remains a vital hub for R&D, with long-term growth prospects fueled...
Shedding weight may no longer be a prickly issue as Eli Lilly’s weight-loss pill moves closer to launch
Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg dose over 40 weeks. While less potent than injectable Wegovy, orforglipron offers a needle-free alternative, potentially easing distribution, especially...
Health ministry in talks to shield India’s pharma industry amid impending tariffs from team Trump
India's health ministry is actively exploring strategies to protect its pharmaceutical industry from potential US tariffs. Discussions involve a fixed tariff regime and waiving import tariffs on US pharma products. The US is also raising concerns about nutraceutical imports, prompting India to consider regulatory changes, potentially impacting the...
Divi's Lab inks supply pact with global pharmaceutical entity
Divi's Laboratories announced a long-term supply agreement with a global pharmaceutical company, focusing on manufacturing and supplying advanced intermediates. The company anticipates significant revenue generation from this partnership.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KBMRzNm
via IFT...
Govt bans select cough syrups for kids below 4 years
The government has prohibited cough syrups containing chlorpheniramine maleate and phenylephrine hydrochloride for children under four due to safety concerns. Drug regulators are mandating manufacturers to include explicit warnings on labels and packaging. This decision follows recommendations from India's apex drug body after examining the fixed-dose...
Alembic Pharma gets USFDA nod for generic drug
Alembic Pharmaceuticals has received the United States Food and Drug Administration approval. The approval allows them to market Carbamazepine tablets in the US. This medication is a generic version of Tegretol Tablets. Carbamazepine tablets are anticonvulsants. They also treat pain from trigeminal neuralgia. The market size for these tablets is estimated...
Assam govt plans to transform GMCH into one of India's largest hospitals
Assam Chief Minister Himanta Biswa Sarma is undertaking steps to transform Gauhati Medical College and Hospital into one of India's largest. The upcoming Mother and Child Care Hospital on GMCH premises will offer specialized pediatric care with 800 beds.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lYoetgL
via IFT...
Trump’s executive order on drug pricing could be a booster for Indian pharma industry
Donald Trump's healthcare revamp, emphasizing generics and biosimilars, could boost Indian drug makers, who already supply 40% of US generic imports. While the move aims to lower drug costs for Americans, potential tariffs on pharma imports create uncertainty.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LtGwUZb
via IFT...
In major development in pharma, halt order enforced on production and sale of 35 fixed-dose combination drugs
India's drug regulator, CDSCO, has ordered a halt to the production, sale, and distribution of 35 fixed-dose combination (FDC) drugs due to safety concerns. These drugs, including pain relievers and diabetes medications, lacked proper evaluation before approval. The CDSCO has directed state and Union territory regulators to reassess approval procedures,...
Mercury soars, and so do sales of rehydration drinks in India
India is experiencing a surge in demand for dehydration-preventing drinks due to the intense heatwave. Electral sales have jumped 27% in March, leading the oral electrolyte market's growth. Doctors are reporting an increase in digestive disorder cases, further fueling the need for rehydration solutions as temperatures rise and waterborne diseases become...
AstraZeneca Pharma India surrenders marketing authorisation of prostate cancer drug
AstraZeneca Pharma India has voluntarily surrendered the marketing authorisation for its prostate cancer drug Olaparib (Lynparza) 100mg and 150mg in India, citing commercial reasons. The company clarified that the drug was never marketed in India since receiving approval in November 2023 and that the decision is unrelated to safety or efficacy concerns.
from...
Biocon Biologics secures market entry for Yesafili in US
Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili, its biosimilar to Eylea. The agreement allows Biocon Biologics to launch Yesafili in the US by the second half of 2026, or earlier under certain conditions. Yesafili, already approved by the USFDA, is intended...
Sweet Surrender: Sanofi puts star insulin brand Lantus up for sale, eyes Rs 2,000 crore from Indian pharma giants
Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licensing agreement remains a possibility. The asking price has been reduced to ₹2,000 crore due to declining sales and government price cuts. Despite newer insulin options, Lantus remains a market leader in India's growing...
Pharma companies may feel heat of US tariffs on China
India's pharmaceutical industry is bracing for potential disruptions due to US tariffs on Chinese goods. Experts warn that China may increase prices for key pharmaceutical ingredients exported to India to offset tariff costs. With India heavily reliant on China for APIs and intermediates, this could lead to higher medicine production costs.
from Healthcare/Biotech-Industry-Economic...
'Factually incorrect': Dr Reddy's denies 25% workforce cost reduction claim
Dr. Reddy's Laboratories has refuted a media report alleging a significant workforce cost reduction initiative. The report claimed the company aimed to cut manpower expenses by 25%, prompting high-salaried employees, including those earning over ₹1 crore annually, to resign. Voluntary retirement was also reportedly offered to R&D employees aged...
Dr Reddy’s slashing jobs to cut costs by 25%; asks several Rs 1 crore+ earners to resign
Dr. Reddy's Laboratories is implementing cost-cutting measures, aiming to reduce manpower expenses by 25%. High-salaried employees, including those earning over ₹1 crore annually, are being asked to resign. The R&D division is offering voluntary retirement to employees aged 50–55. Some divisions, like digital therapeutics, may face shutdowns or...
India's healthcare expenditure expected to surge from 3.3% to 5% of its GDP by 2030: CareEdge
India’s healthcare spending is projected to rise from 3.3% to 5% of GDP by 2030, according to a CareEdge report. The sector is poised for major transformation driven by investments, government initiatives, and demographic shifts.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ShcUkJe
via IFT...
Glenmark, Sun Pharma, Zydus recall products in US
Glenmark, Sun Pharma, and Zydus are recalling various products in the US due to manufacturing issues and CGMP deviations, according to the USFDA. Glenmark is recalling over 25 products, while Sun Pharma is recalling Gabapentin capsules due to cross-contamination. Zydus is recalling chlorproMAZINE Hydrochloride Tablets due to an impurity exceeding the...
Healthcare investors go for full-body check-up: Forensic due diligence rise as sector faces scrutiny
Investors are increasingly scrutinizing India's healthcare sector, including pharma companies and hospitals, due to concerns about potential malpractices and regulatory scrutiny. They are conducting in-depth due diligence, examining doctor-management relationships, referral practices, and the appropriateness of treatments. This heightened scrutiny...
Any tariffs on pharma sector would be counterproductive for Americans: Wockhardt Chairman Habib Khorakiwala
Wockhardt Chairman Habib Khorakiwala warns that potential US tariffs on pharmaceutical products would harm Americans. He highlights India's crucial role in supplying 40% of US prescription drugs at reasonable prices. Imposing tariffs would increase healthcare costs for Americans, given the lengthy FDA approval process and higher manufacturing and research...
Weight is over! Pharma companies race to make weight-loss drug semaglutide
Indian drugmakers, including Dr. Reddy's and Zydus Lifesciences, are investing heavily in manufacturing capabilities to launch generic versions of Novo Nordisk's Wegovy and Ozempic as patents expire. These companies are developing novel technologies and aligning capacities for delivery pens, targeting both the Indian market and exports.
from Healthcare/Biotech-Industry-Economic...
USFDA issues Form 483 with 11 observations to Raleigh plant of Aurobindo Pharma arm
Aurobindo Pharma Ltd announced that the USFDA issued a Form 483 with 11 observations following an inspection of its Aurolife Pharma LLC's Raleigh plant in North Carolina. The company stated that the observations are procedural and it will respond with corrective actions. Aurobindo Pharma anticipates no significant impact on its operations or supplies...
Morepen to hire 1,000 medical representatives to strengthen formulations biz
Morepen Laboratories plans to significantly expand its medical representative team, adding over 1,000 members in the next three years, with 200 joining in FY26. This strategic move aims to bolster its formulations business and capture a larger share of the growing Indian pharmaceutical market, targeting Rs 1,000 crore in five years.
from Healthcare/Biotech-Industry-Economic...
Cipla gets USFDA nod for generic cancer drug
Cipla has secured USFDA approval to market a generic version of Abraxane, paclitaxel protein-bound particles for injectable suspension (100 mg/vial). This medication is indicated for treating metastatic breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hv3QJnr
via...
Tariff risks cloud near-term pharma deals outlook: Rothschild's Stefano Beschi
Uncertainty surrounding potential US tariffs is threatening to disrupt India's booming pharma deal market, according to Rothschild & Co. While short-term M&A activity may slow due to a lack of confidence and predictability, the industry remains resilient in the long run.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u4w5GE3
via...
US court lifts restrictions on Sun Pharma launching autoimmune disorder drug
Sun Pharmaceutical Industries Ltd announced that a US court has ruled in its favour, immediately vacating a preliminary injunction that restricted the launch of LEQSELVI, a drug for treating autoimmune-related hair loss. This decision follows a patent infringement litigation with Incyte Corporation.
from Healthcare/Biotech-Industry-Economic Times...
Natco to sell rare spinal disease drug Risdiplam for ₹15,900
Each bottle of Risdiplam lasts around 12 days and that will take the cost to roughly ₹30,000 per month for the patient. Sources said Roche sells Risdiplam on a discounted basis or one bottle free for each bottle purchased.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3lyOqN4
via IFT...
ZIM Labs inks pact with Globalpharma Co to commercialise oral thin film products
ZIM Laboratories Ltd has entered into a licensing and supply agreement with UAE-based Globalpharma Co. to commercialize oral thin film (OTF) products in the Gulf Cooperation Council (GCC) region. The agreement involves a dossier license, product supply, and technology know-how license for ZIM's proprietary 'ThinOral' OTF technology platform.
from...
Trump signals major tariff on pharma imports, Indian drugmakers could face impact
Donald Trump announced a forthcoming "major" tariff on pharmaceutical imports, aiming to incentivize drug companies to relocate operations to the U.S. He also stated he warned Taiwan Semiconductor Manufacturing Company (TSMC) about potential taxes if they didn't establish U.S. plants. Trump criticized the Biden administration's $6.6 billion grant to...
As Empagliflozin goes off patent, 71 copies of the key diabetes drug roll out in a month
Following the expiration of Empagliflozin's patent, the Indian pharmaceutical market has seen a surge, with 71 new brands and 17 companies introducing their versions. This influx has significantly increased sales, driven by prices that are 80-90% lower than the original. The increased affordability is expected to improve access for a wider population,...
India's anti-obesity drug market has grown more than fourfold in the last five years
India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven by lifestyle diseases and increased affordability. Semaglutide, particularly Rybelsus from Novo Nordisk, dominates the market, accounting for 69% of sales. The introduction of Mounjaro by Eli Lilly has further fueled acceptance,...
India’s anti-obesity drug market quadruples in five years on lifestyle disease surge
India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025. Semaglutide pill Rybelsus is a key driver, capturing 69% of the market. The introduction of Mounjaro and upcoming launch of Wegovy are expected to further accelerate growth, driven by rising lifestyle diseases and increased willingness...
PE firms bet on small-town hospitals for a growth shot
Non-metro locations, such as Lucknow , Vizag, Jaipur, Cochin, Siliguri, Guwahati, Bhubaneswar and Patna, private equity investors believe, hold great growth potential in healthcare, in lockstep with an increasing affordability quotient in tier- 2 or 3 towns, and a greater availability of qualified doctors and specialists.
from Healthcare/Biotech-Industry-Economic...
Sun Pharma launches medication for Erosive Esophagitis
Sun Pharmaceutical Industries has launched Fexuprazan tablets (40 mg) in India, branded as Fexuclue, to treat Erosive Esophagitis of all grades. Developed in collaboration with Daewoong Pharmaceutical, the drug showed over 95% healing efficacy in a Phase 3 study. This new treatment aims to meet the significant unmet medical need for this condition.
from...
Novo Nordisk readies to bring weight-loss drug Wegovy to India
Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to outperform Eli Lilly's Mounjaro. Regulatory approval for Wegovy's cardiovascular benefits has been granted, pending final approval, allowing cardiologists to prescribe it.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pK6I3uf
via...
Govt plans capacity building activities for frontline workers of HPV vaccination
The Union Health Ministry plans to initiate capacity-building activities for frontline workers administering the HPV vaccine to girls aged 9-14 years to prevent cervical cancer. Following recommendations, the Ministry is finalizing strategies for this initiative. India accounts for a significant portion of global cervical cancer cases, with the vaccines...
Indians are quitting the safety net of health insurance; GST and high premiums are only part of the problem
Rising health insurance premiums and frequent claim rejections have led more Indians to drop their coverage. Despite the introduction of GST and government schemes, escalating costs leave many struggling to afford insurance, prompting calls for regulatory reforms to stabilize healthcare expenses.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vrU5ClS
via...
Kerala launches digital payment system, online services in govt hospitals
Kerala Health Minister Veena George announced the introduction of digital payment systems in 313 government hospitals to facilitate various service fee transactions. This system, part of the e-health initiative, employs POS devices from State Bank of India and Canara Bank, and includes capabilities such as the M-Health app and QR code-based ticket...
Now Pharma Inc looks for cure as Trump delivers dose of anxiety
US President Trump has announced that new tariffs on pharmaceuticals will be introduced soon, creating uncertainty for India's drug makers. Industry insiders are considering alternative markets to offset potential impacts, with companies preparing for any eventual developments.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T6McNyK
via...
T-Rx: Indian pharma majors breathe easy as US spares sector from reciprocal tariffs
Large Indian drug manufacturers experienced relief as President Trump's administration decided against imposing expected reciprocal tariffs on pharmaceuticals, which could have significantly impacted their earnings. Analysts deem future tariffs unlikely due to potential drug shortages and the influence of major pharma companies investing in the US.
from...
'Pharma's exemption from reciprocal tariffs underscores generic medicines' critical role globally'
The US Administration has exempted pharmaceuticals from reciprocal tariffs, highlighting the significance of affordable, life-saving generic medicines. The decision supports the vital trade partnership between India and the US, with Indian pharmaceutical companies supplying a substantial proportion of drugs to American residents and generating significant...
Big relief for India! Trump spares pharma from harsh tariffs
US President Trump has exempted India's pharmaceuticals from new reciprocal tariffs, benefiting the major export industry. This exemption highlights the significance of India's cost-effective generic medicines in US healthcare. The White House noted that removing trade barriers in other sectors could increase US exports by $5.3 billion annually.
from...
Fortis healthcare buys disputed Fortis trademark for Rs 200 crore
Fortis Healthcare has acquired the Fortis trademark from its former promoters, the Singh brothers, for Rs. 200 crore through a court-sanctioned auction. The trademark was involved in a litigation case with Japan's Daiichi Sankyo. Fortis Healthcare, now owned by IHH Healthcare, operates a network of 26 hospitals nationwide.
from Healthcare/Biotech-Industry-Economic...
Lupin acquires UK-based firm for 12.3 million pounds
Lupin has acquired UK-based Renascience Pharma for £12.3 million, enhancing its branded medicine portfolio. The acquisition allows Lupin to expand in the UK market with Renascience's products for infectious diseases, ear pain, and cardiovascular and renal treatment. This move supports Lupin's mission to provide accessible healthcare solutions.
from...
Market volatility derails Novartis' plan to sell stake in its India arm
Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation. Despite strategic reviews and potential interest, fluctuations in stock prices and declining sales present hurdles in reaching a deal, with existing licensing agreements adding complexity.
from Healthcare/Biotech-Industry-Economic...
360 ONE, Claypond Capital get CCI nod to acquire stakes in API Holdings
Fair trade regulator CCI has approved 360 ONE and Claypond Capital Partners' joint proposal to acquire stakes in API Holdings. This transaction involves purchasing compulsorily convertible preference shares from MEMG Family Office LLP, indicating oversight to prevent unfair business practices and ensure fair competition.
from Healthcare/Biotech-Industry-Economic...
View: Will Trump's tariffs lift the veil on India's drug safety problem?
India’s pharmaceutical industry is facing potential tariffs imposed by President Trump, which could significantly impact exports, particularly to the US. High export dependence and questionable quality standards underscore the need for reform and improved regulation to maintain the industry’s reputation and market position.
from Healthcare/Biotech-Industry-Economic...
Ankura Hospitals secures Rs 165 cr funding from ADB
Ankura Hospitals has secured Rs 165 crore in funding from the Asian Development Bank. This strategic investment will enhance its pediatric, maternity, and gynecology services, enabling the Hyderabad-based chain to expand its facilities and strengthen its presence in key cities across India.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hmIAXlY
via...
KKR in talks to acquire US dental labs chain Leixir
Global investment firm KKR is in talks to acquire Leixir Dental Laboratory Group from Comvest Investment Partners at a valuation of $200-$250 million. Leixir, founded in 2013, offers various dental solutions and operates facilities in the US and India. Deloitte is advising on the sale process.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Aeon5HM
via...
From AI to Telemedicine: Digital skills every healthcare professional should learn
Digital skills are crucial for healthcare professionals, with growing fields like telemedicine, AI-driven diagnostics, and data analytics. Continuous learning in electronic health records, cybersecurity, and emerging technologies like 3D printing and robotics is vital for those seeking to stay relevant and succeed in the evolving healthcare landscape.
from...
Eli Lilly working on a heart drug that may benefit Indians: CEO David Ricks
Eli Lilly is developing a groundbreaking drug, lepodisiran, to combat high LPA cholesterol levels prevalent in South Asians, potentially reducing it by 85%-90%. With heart disease cases surging in India, this phase 3 trial drug promises significant cardiovascular benefits, requiring only once-a-year administration. It's crucial, given the rising heart...
47 drugs found 'not of standard quality' in February
The Central Drugs Laboratories identified 47 drug samples as 'not of standard quality' in February, while State Drugs Testing Laboratories found 56 similar samples. One drug from West Bengal was found spurious and made by an unauthorized manufacturer. Regular action is taken to remove such drugs from the market.
from Healthcare/Biotech-Industry-Economic...
Essential medicines will cost you a bit more from April 1
Beginning April 1, prices for essential drugs like painkillers, antibiotics, and anti-diabetic medicines will rise by 1.74%. The increase is based on the change in the wholesale price index. The pharmaceutical industry is pushing for higher price hikes to counterbalance increased input costs over recent years.
from Healthcare/Biotech-Industry-Economic...
Kedaara, TA Associates vie for minority stake in Sagent Pharma
Kedaara Capital and TA Associates are in talks to acquire a significant minority stake in Sagent Pharma, valued at $500-600 million. Investment amounts are estimated between $150-200 million. Originally acquired by Ravi Penmetsa's Ellimist Singapore, Sagent specializes in generic injectables for the US market.
from Healthcare/Biotech-Industry-Economic...
Donor aid cuts may undo years of progress in combating HIV: Study
US President Trump's decision to suspend USAID programmes and fund cuts by other countries could lead to 10.8 million new HIV infections and 2.9 million HIV-related deaths by 2030 in low-and-middle-income countries. Major donor funding cuts may reverse decades of progress against HIV/AIDS, especially in sub-Saharan Africa and among vulnerable populations.
from...
Delhi HC asks Natco Pharma to pause Risdiplam launch amid patent dispute
The Delhi High Court has ordered Natco Pharma to maintain status quo on the launch of Risdiplam until April 2. Roche, which holds the patent for the drug, sought an injunction to prevent Natco from manufacturing it in India. The court highlighted the public interest in making the drug affordable.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kI9mxiE
via...
Open to tie-ups in India for selling Mounjaro: Eli Lilly CEO David Ricks
Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, recently launched in India. Priced significantly lower than in the US, Mounjaro's introduction anticipates strong demand in the country with over 100 million obese and diabetic individuals.
from Healthcare/Biotech-Industry-Economic...
Eli Lilly's goal is to reach everyone who needs obesity care: Global CEO David Ricks
Eli Lilly's CEO David Ricks discusses the launch of diabetes and anti-obesity drugs Mounjaro and Zepbound, focusing on expanding access in emerging markets. He highlights new weight-loss drugs and emphasizes the importance of partnerships, including with Indian tech companies and governments, for tackling chronic diseases and improving public health...
India develops its first indigenous MRI machine, to reduce treatment costs
India has developed its first indigenous MRI machine to be installed at AIIMS Delhi by October for trials, reducing dependency on imports by 80-85%. An MoU was signed with SAMEER for the installation. The Ministry of Electronics and Information Technology is spearheading this technological advancement aimed at achieving self-reliance in medical technology.
from...
Meghalaya’s Gnanamma Healthcare Centre transitions to near net-zero electricity health facility
Gnanamma Healthcare Centre in Guwahati celebrates its transition to a near net-zero electricity facility with a new 6.05kW solar plant and battery energy storage. This upgrade ensures reliable power, especially for critical services like vaccine storage and emergency care, reducing carbon emissions and setting an example for sustainable healthcare...
Delhi HC rejects Roche's plea to block Natco Pharma on Risdiplam patent
The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy drug, citing public interest and high prices. Natco is required to maintain detailed financial records and may owe damages if Roche ultimately wins the case.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zsjncES
via...
Heartening news: Device made in India to help transplant patients
India plans to develop cost-effective left ventricular assist devices (LVADs) to aid end-stage heart failure patients while they wait for donor hearts. With an estimated 50,000 patients needing heart transplants annually but a severe shortage of donor hearts, indigenously made LVADs could reduce costs and increase foreign medical visitors. Development...
₹14,000 per month weight-loss shot is here to cash in on India’s obesity crisis
India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce weight-loss drugs in the market. The economic impact is enormous, and local generics are preparing to offer more affordable alternatives to combat this growing health issue.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1XhQp5n
via...
Bharat Biotech invests Rs 600 cr to expand into cell, gene therapies
As per Bharat Biotech, the facility will tackle scientific challenges such as targeted gene expression, immune system modulation, and long-term cell survival. Work will span from boosting immune responses against cancer to ensuring that therapeutic proteins are safely accepted in patients with genetic diseases like haemophilia.
from Healthcare/Biotech-Industry-Economic...
Entero Healthcare launches HealthEdge programme for chemists
Entero Healthcare Solutions launched the 'HealthEdge' program to modernise retail pharmacies and improve efficiency for over 86,000 chemists. The company also acquired the Aayu Chemist app and Medcords platform, aimed at enhancing profits and customer engagement. Entero reported significant revenue and profit growth in FY 2025 Q3.
from Healthcare/Biotech-Industry-Economic...
Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval
Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. With rising obesity and diabetes rates, India presents a significant market opportunity for the U.S.-based company. Mounjaro is already marketed in the UK and Europe for both conditions and under the name Zepbound for obesity in the U.S.
from...
India has a chance to lead in health space amid Global North's funding cuts: Gates Foundation CEO Mark Suzman
Mark Suzman, CEO of the Gates Foundation, sees the current global funding challenges as an opportunity for India to lead, particularly in health and development. Amid funding cuts from the US, UK, and France, Suzman remains optimistic about mobilizing resources for life-saving initiatives, highlighting India's cost-effective innovations.
from Healthcare/Biotech-Industry-Economic...
Impose safeguard duties on medical devices: AiMeD
The Association of Indian Medical Device Industry (AiMeD) has requested the government to impose safeguard duties on 12 medical device categories to shield domestic manufacturers from cheap imports. AiMeD highlighted a significant increase in imports, notably in syringes and needles, primarily from China, the US, and Singapore.
from Healthcare/Biotech-Industry-Economic...
AI, teleconsultation, modern tech being used in treatment, diagnosis: Nadda
Health Minister JP Nadda emphasized the government's commitment to enhancing healthcare through policies incorporating AI for TB detection, modern cancer treatments, and mental health teleconsultation. The goal is to increase health expenditure to 2.5% of GDP, currently at 1.84%, showcasing substantial achievements in improving maternal and child mortality...
Health expenditure now at 1.84 pc of GDP, moving steadily to 2.5 pc: JP Nadda
Union Health Minister JP Nadda stated that the Indian government’s health expenditure has reached 1.84% of GDP, moving towards the 2.5% target by 2025. From 2013-14's Rs 38,000 crore, current health allocations are nearly Rs 1 lakh crore. The National Health Policy 2017 aims to increase healthcare funding, with 1.
from Healthcare/Biotech-Industry-Economic...
Zydus Lifesciences gets USFDA nod to produce prostate cancer treatment drug
Zydus Lifesciences Ltd has received final approval from the USFDA to manufacture 60 mg Apalutamide tablets for prostate cancer treatment. These tablets will be produced at their Ahmedabad facility. Apalutamide, an androgen receptor inhibitor, is intended for metastatic castration-sensitive prostate cancer and had annual sales of USD 1,099.8 million...
India weighs lower tariffs for US medical devices amid trade talks
The Indian government is considering lowering tariffs on US medical devices to mitigate potential US tariff threats on Indian exports. While this aims to ease trade tensions, industry experts express concerns about the impact on India's self-reliance. Stakeholders suggest reciprocal market access as Indian exporters face high regulatory barriers in...
Gene therapy for blood cancer shows 73 per cent response rate in clinical trials
Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low and middle-income countries, patients in whom 'B-cell' tumours continue to grow following a period of remission (relapse), or do not respond to treatment (refractory), suffer from poor outcomes due to an absence of effective therapies.
from...
AIIMS critically short of staff amid land & budgetary issues
AIIMS in New Delhi is experiencing severe staff shortages, with hundreds of vacant posts for doctors and faculty members. A parliamentary committee has urged the health ministry to offer competitive compensation and prioritize the filling of these positions. Additionally, the slow progress of AIIMS' expansion projects has been criticized.
from Healthcare/Biotech-Industry-Economic...
Sun Pharma, Zydus recall products in US: USFDA report
Sun Pharma and Zydus Pharmaceuticals are recalling products in the US market due to manufacturing issues, according to the USFDA. Sun Pharma is recalling Morphine Sulfate tablets for failed dissolution specifications, while Zydus is recalling Nelarabine Injection for failed impurities/degradation specifications.
from Healthcare/Biotech-Industry-Economic...
Skin cream, nasal spray, and... blindness? AIIMS doctors warn steroids misuse could trigger silent vision loss
Frequent use of steroid-based treatments for respiratory issues, allergies, and skin conditions can heighten the risk of glaucoma. Experts at AIIMS stress the importance of regular eye check-ups for early detection. Lifelong care and awareness programs at the primary care level are essential for preserving vision.
from Healthcare/Biotech-Industry-Economic...
Struggling with dry eyes? Haldi's power-packed compound might be the relief you need
A study by AIIMS reveals that bio-enhanced curcumin, found in turmeric (haldi), effectively treats mild to moderate dry eye disease by improving tear stability and reducing inflammation. The clinical trial showed significant improvements in tear metrics and symptoms, suggesting a natural, side-effect-free alternative treatment.
from Healthcare/Biotech-Industry-Economic...
China’s biotech is redrawing the global pharma map; what India can learn
American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma treatment. AstraZeneca signed a deal with CSPC Pharma for a cardiac treatment, while Merck signed a $2 billion deal with Hansoh Pharma. Indian drugmakers are also collaborating with Chinese rivals. Mankind Pharma partnered with...
Parliamentary panel flags brain drain from health dept, delay in filling vacancies in research posts
A parliamentary committee has raised concerns about unoccupied posts of scientists in the Department of Health Research and recommended stopping contractual appointments to prevent brain drain. The panel emphasized enhancing higher education and research infrastructure, improving standards of living, and offering competitive pay to retain Indian professionals.
from...
Parl panel on health: Cos scared to set up units due to CDSCO approach
The Parliamentary Standing Committee on Health and Family Welfare criticized the Central Drugs Standard Control Organisation (CDSCO) for delays and lack of transparency in the drug licensing process. They recommended streamlining the system and establishing an independent advisory board to improve India's medical device industry.
from Healthcare/Biotech-Industry-Economic...
Dr. Reddy’s recalls mislabelled Levetiracetam injection in the US; patients likely to experience 'adverse' events
Dr. Reddy’s Laboratories is recalling a batch of Levetiracetam injection bags in the U.S. due to incorrect labeling, which could result in patients receiving a double dose. The error poses serious health risks, including hypersensitivity, liver injury, and respiratory depression. The mislabeled batch was distributed nationwide between November 4 and...
Indian generic drugs linked to deaths in US? Trade group slams study blaming desi pharma
A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared to domestic drugs. The findings have drawn criticism from the Indian Pharmaceutical Alliance, which disputes the study’s methodology and its implications on quality and efficacy.
from Healthcare/Biotech-Industry-Economic Times...
Global buyout funds line up for AGS Health
Global buyout funds are eyeing AGS Health, valuing the IT firm at around $1 billion. EQT Partners, the current owner, plans to launch the sale early next year. AGS Health, acquired by EQT in 2019 for $320 million, provides RCM services with 12,000 employees and significant revenue. Interest in healthcare BPOs is rising among private equity firms.
from...
New affordable diabetes drug Empagliflozin launched in India
Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices following the expiration of Boehringer Ingelheim’s patent. Mankind Pharma’s version is priced at Rs 5.50 per tablet, a reduction of 90%. This move is expected to improve access to affordable diabetes treatment in India.
from...
Zydus eyes major stake in French medtech Amplitude for Rs 2,446 crore
India's Zydus Lifesciences is set to acquire an 85.6% stake in France's Amplitude Surgical for nearly $280 million to expand in the global medical devices market. The acquisition, at a premium of nearly 81% to Amplitude's last close, aims to leverage growth opportunities in surgical technologies for lower-limb orthopedics and expand internationally.
from...
India, vaccine superpower; manufactures 60% of global supply: ICMR former chief
India's Thiruvananthapuram has become a vaccine superpower, producing 60 per cent of the world's vaccines, with significant contributions from Pune. India's efficient vaccine development and distribution, spearheaded by government-supported research and a National Task Force, have positioned the country as a leader in global health. This effort notably...
Zydus Lifesciences to buy 86% stake in French medical devices maker
India's Zydus Lifesciences is set to acquire an 85.6% stake in France's Amplitude Surgical for nearly $280 million to expand in the global medical devices market. The acquisition, at a premium of nearly 81% to Amplitude's last close, aims to leverage growth opportunities in surgical technologies for lower-limb orthopedics and expand internationally.
from...
ET Q&A: All our products are legitimate, sold under valid prescriptions, says Aveo Pharmaceuticals MD
Aveo Pharmaceuticals asserts that a stop-production notice was issued due to non-compliance with GMP standards, not for exporting opioid-based drugs. They have taken corrective measures and are working with authorities, aiming to resume operations soon, as many livelihoods depend on it.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5FvT3o8
via...
India's Syngene International acquires first US biologics facility for $36.5 million
India's Syngene International has agreed to acquire its first biologics facility in the U.S. from Emergent Manufacturing for $36.5 million. This move aims to expand Syngene's capabilities in the Northeast U.S. and reduce dependence on China, with the facility expected to be operational by mid-2025.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IT3gfWs
via...
Zydus Lifesciences gets USFDA nod to market generic antifungal shampoo
Zydus Lifesciences received approval from the USFDA to market Ketoconazole Shampoo, an antifungal medication, in the US. This approval is for a generic version targeting dandruff and various fungal infections. The medication will be produced at Zydus's manufacturing site in Ahmedabad. As of January 2025, its annual US sales were valued at USD 68.89...
Sun Pharmaceuticals to acquire Checkpoint Therapeutics for $355 mn
Sun Pharmaceuticals will acquire Checkpoint Therapeutics for $355 million, bringing the FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, UNLOXCYT, to a broader market. The acquisition enhances Sun Pharma's oncology portfolio and aims to provide a new treatment option for cSCC patients. Completion is expected by the...
Keep tobacco and alcohol ads and their proxies off IPL, Health ministry tells cricket board
The health ministry has urged the IPL and cricket board to ban all tobacco and alcohol advertising at matches and related events, and on national TV broadcasts. The letter emphasizes the crucial role of sports in promoting public health, noting that tobacco and alcohol are major risk factors for non-communicable diseases, which account for over 70%...
USFDA pulls up Granules India for lapses in maintaining storage facilities, equipment at Telangana plant
The USFDA has issued a warning to Granules India for contamination and improper equipment maintenance at its Telangana facility. Inspectors found significant contamination, bird droppings, and torn CGMP records during their visit. The agency demands prompt corrective actions from the company to rectify these violations, emphasizing the need for effective...
Protecting your heart and managing diabetes: The power of a holistic lifestyle
Adopting a holistic lifestyle can significantly improve heart health and manage diabetes. Key strategies include a balanced diet, regular physical activity, stress management, maintaining healthy weight, and regular health check-ups. These habits are crucial for reducing the risk of heart disease and improving overall well-being.
from Healthcare/Biotech-Industry-Economic...
Indian Pharmaceutical Alliance calls for zero import duty on US drugs to boost local industry
The Indian Pharmaceutical Alliance (IPA) has proposed reducing the import duty on pharma products from the US to zero. Currently, India imposes a 10% tariff on US drugs, but the US does not charge any import duty on Indian drugs. This suggestion aims to support the Indian pharma industry by lowering costs.
from Healthcare/Biotech-Industry-Economic...
Registration for Ayushman Bharat to start after March 8: Delhi health minister
Delhi Health Minister Pankaj Singh announced that the registration for the Ayushman Bharat scheme in the national capital will begin after March 8. He assured that significant improvements in healthcare infrastructure and transparency in hospital operations would be implemented within 100 days, emphasising a focus on economically weaker sections and...
Apollo Health picks up controlling stake in Lucknow-based Care Diagnostics
Apollo Health & Lifestyle Limited has obtained a significant controlling stake in Care Diagnostics through an all-cash deal. This strategic partnership will position Care Diagnostics to expand its healthcare testing services more widely across Uttar Pradesh, with plans to achieve full acquisition eventually.
from Healthcare/Biotech-Industry-Economic...
AstraZeneca gets nod to import, sell hyperkalaemia treatment drug in India
AstraZeneca Pharma India Ltd has received approval from India's drug regulator to import and sell sodium zirconium cyclosilicate powder for treating hyperkalaemia in adults. This clearance enables the launch of Lokelma in India, contingent on obtaining related statutory approvals.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dKLQ2F9
via...
Lasik surgery in 10 seconds? This AI-powered tech may challenge the traditional course of treatment for eye care
A city-based private eye hospital has introduced a breakthrough in LASIK surgery, achieving treatment time under 10 seconds per eye using AI technology. This innovation enhances accuracy and offers personalized treatment plans, consistently achieving a 99% to 100% success rate, designed to quickly and effectively correct vision for suitable patients.
from...
Clinical research entities asked to register by April 1
India's drug regulatory authority mandates all clinical research organisations to register through the SUGAM portal by April 1 to enhance transparency and accountability in the industry. This move aims to hasten clinical trials and create a comprehensive database of clinical research organisations, with India currently contributing just 3-4% to global...
Aurobindo unit terminates pact with Singapore firm to develop pentavalent vaccine
Aurobindo Pharma has terminated a license agreement through its subsidiary Auro Vaccines with Hilleman Laboratories for developing a pentavalent vaccine for children. The company asserted that this step would not materially affect its financial situation, as Auro Vaccines is not a crucial subsidiary. Despite this, Aurobindo Pharma shares rose 3.83%...
India set to introduce list of OTC drugs this month
India is set to receive a list of drugs transitioning to over-the-counter (OTC) status from prescription-only status soon. The committee responsible is finalizing the report to ensure public health is not at risk, with the report to be submitted to the Drugs Technical Authority Board shortly.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LCyYDsi
via...
Senores Pharma to acquire 14 ANDAs from Dr Reddy's Laboratories
Senores Pharmaceuticals of Gujarat has signed an agreement to acquire 14 Abbreviated New Drug Applications from Dr Reddy's Laboratories. The acquisition, funded through IPO proceeds, includes 13 USFDA-approved ANDAs. This expands Senores' product offerings in the US and other regulated markets, addressing an opportunity worth USD 421 million.
from...
Zydus to develop combination vaccine for shigellosis and typhoid
Zydus Lifesciences is set to develop a combination vaccine against shigellosis and typhoid with the Gates Foundation's support. The vaccine aims to protect children under five in regions where both diseases are prevalent. Early-stage development and studies are scheduled to begin in March 2025. Collaboration with partners leverages Zydus' expertise...
Diabetes and obesity: The dangerous duo you need to break up with
World Obesity Day, observed on March 4th, emphasizes the dangers of the combined effects of diabetes and obesity, termed 'diabesity.' This harmful partnership increases the risk of severe health issues like heart disease, kidney damage, and nerve pain. The observance calls for lifestyle changes and medical interventions to manage and break free from...
AstraZeneca Pharma India gets CDSCO approval to import, sell cancer treatment medicine
AstraZeneca Pharma India has received approval from CDSCO to import and distribute the cancer treatment drug Durvalumab solutions. This approval allows the marketing of Durvalumab in combination with Tremelimumab for treating unresectable hepatocellular carcinoma in India, pending related statutory approvals.
from Healthcare/Biotech-Industry-Economic...
Sun Pharma aims to launch anti-obesity and type 2 diabetes drug Utreglutide in five years: Dilip Shanghvi
Sun Pharmaceutical, India's largest drugmaker by revenue, plans to launch its experimental anti-obesity and type 2 diabetes drug Utreglutide in the next four to five years, said Managing Director Dilip Shanghvi. The drug is a GLP-1 receptor agonist and has shown promising results in early trials. Sun Pharma is focusing on launching the drug in India...
Glenmark acquires Acetylcysteine injection, launches in US market
Glenmark Pharmaceuticals Ltd acquired the generic version of Acetylcysteine injection from Aspen Pharma USA Inc and launched it in the US market. The injection is used to treat acetaminophen overdose and is expected to have the same therapeutic effect as the listed drug Acetadote Injection.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ghFB3pL
via...
Glenmark recalls 15 lakh bottles of ADHD medication in US: USFDA
Glenmark Pharmaceuticals is recalling around 14.76 lakh bottles of Atomoxetine Capsules due to detected CGMP deviations and the presence of N-Nitroso Atomoxetine impurity above FDA recommended limits. The recall is classified as Class II, indicating potential temporary or medically reversible adverse health consequences.
from Healthcare/Biotech-Industry-Economic...
Reciprocal tariffs may make Indian generic drugs costlier in US: Pharma giants on Trump stance
Indian pharmaceutical industry leaders indicate that proposed US tariffs on pharmaceutical exports may lead to increased drug costs and potential shortages in the US. They argue that the tariffs might be absorbed by consumers and stress the significant cost savings that affordable Indian generics provide to the US healthcare system.
from Healthcare/Biotech-Industry-Economic...
Our healthcare, education systems being plagued by commodification and commercialisation: Dhankhar
Vice President Jagdeep Dhankhar emphasized that healthcare and education should not be driven by commodification and commercialisation. Speaking at KPB Hinduja College in Mumbai, he highlighted the importance of Sanatan in India's culture for its inclusivity and its role in fostering equality through education.
from Healthcare/Biotech-Industry-Economic...
Aim to open 20,000 Jan Aushadhi centers by the end of 2025: Union Health Minister JP Nadda
Union Health Minister JP Nadda flagged off the Jan Aushadhi Raths for the Jan Aushadhi Saptah from March 1 to 7, aiming to open 20,000 Jan Aushadhi centres by the end of 2025. Events during the week will raise awareness about affordable generic medicines. Sanitary pads will also be offered at Rs 1 to promote menstrual hygiene.
from Healthcare/Biotech-Industry-Economic...
Biocon launches diabetes, obesity management drug in UK
Biocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide. This follows approval from the UK's MHRA, making Biocon the first generics company to gain such approval in a major regulated market.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vB1bDCs
via...
CDSCO revamps NOC process for unapproved drug exports to boost efficiency & reduce manpower pressure
Indian drug regulator CDSCO is streamlining the process for granting No Objection Certificates (NOCs) for unapproved drug exports by moving to blanket, country-specific NOCs based on export history. This change aims to ease manpower pressure and improve regulatory efficiency, reducing annual NOCs significantly.
from Healthcare/Biotech-Industry-Economic...
New NOC process in works for export of unapproved drugs
The Indian drug regulator CDSCO is revamping the process for granting No Objection Certificates (NOCs) for the export of unapproved drugs to reduce manpower pressure and boost regulatory efficiency. Instead of buyer and quantity-specific NOCs, blanket NOCs will be issued based on export history and country approval.
from Healthcare/Biotech-Industry-Economic...
Healthcare experts urge India to rewrite clinical trial rules to boost global market share
Healthcare experts suggest that India could increase its share in the global clinical trials market by learning from countries like China and Australia. India currently holds an 8% share, compared to China’s 29%. Experts emphasize improving regulatory speed, offering incentives, and raising patient awareness for trials. India’s clinical trials market...
AI in healthcare likely to contribute $30 bn to India's GDP by 2025: Report
Artificial Intelligence (AI) in healthcare could boost India's GDP by USD 25-30 billion by 2025, driven by initiatives like the IndiaAI Mission. Despite this, regulatory challenges, limited digital infrastructure, and workforce training gaps hinder faster AI adoption, especially compared to the banking sector.
from Healthcare/Biotech-Industry-Economic...
India's contract drug makers seek government support in China fight
India's contract drug makers are seeking government support to remove regulatory hurdles and speed up raw material import clearances. With potential growth to $22-25 billion by 2035, the industry aims to compete globally, but currently faces delays and higher costs compared to Chinese counterparts.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bH8MIAN
via...
Glenmark launches Epinephrine injection in US
Glenmark Pharmaceuticals has launched a generic version of Epinephrine injection multiple-dose vial in the US, gaining 180 days of CGT exclusivity. The injection treats hypotension from septic shock and allergic reactions. Glenmark's product, bioequivalent to BPI Labs' reference drug, adds to their institutional portfolio and achieved annual sales...
India on the verge of becoming clinical trials hub, Parexel executive says
India is poised to become a prominent site for early-stage clinical trials, particularly amid the disruptions caused by the Russia-Ukraine conflict. Parexel plans to increase its Indian workforce by over 2,000 within five years, citing lower costs and growing market potential. However, challenges such as regulatory inconsistencies and awareness regarding...
Zydus launches vaccine for new strain of influenza virus
Zydus Lifesciences introduces India's first quadrivalent influenza vaccine, VaxiFlu-4, for protection against four new virus strains as per WHO recommendations. The vaccine, developed at Zydus's Vaccine Technology Centre in Ahmedabad, has been cleared by the Central Drug Laboratory and aims to address major public health challenges by preventing flu...
No gym? No problem! 7 fun ways to stay fit at home
Skip the gym and stay fit with fun workouts like swimming, hula hooping, aerial yoga, Zumba, stair running, cycling, and exercise videos. These activities boost strength, endurance, and flexibility at home or outdoors!
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E5FOCAa
via IFT...
Indian drugmakers likely to stay competitive despite planned tariffs, Dr Reddy's says
Indian drugmakers, including Dr Reddy's, are confident about maintaining competitiveness in the generic drugs market despite potential U.S. tariffs on pharmaceutical imports. Dr Reddy's MD, GV Prasad, stated that Indian firms are awaiting more details on the tariffs but emphasized that shifting pharmaceutical production to the U.S. is impractical and...
New cases of breast cancer could be up 38 pc by 2050 globally; related deaths by 68 pc: Study
By 2050, breast cancer cases and deaths are expected to rise significantly, particularly in countries with low human development index. Researchers using the GLOBOCAN database found disparities in diagnosis and mortality rates globally. Improvements in early diagnosis and treatment, along with investing in high-quality cancer data, are essential to...
What explains feverish deal-making in India's hospital sector
India's hospital sector is experiencing a surge in deal-making, with KKR acquiring Healthcare Global for $400 million. This trend highlights the growing investor interest in the sector, driven by the increased demand for quality healthcare services. Factors such as medical tourism, government support, and expanding insurance coverage contribute to...
Amgen to invest $200 million in India site, CEO says
Amgen will invest $200 million in its new technology centre in Hyderabad, India, this year, with plans for further investments. The centre, focused on AI and data science for drug development, will employ around 2,000 people by year-end. The announcement coincides with the BioAsia conference, which will feature global pharmaceutical executives.
from...
Opiod row: Aveo Pharma says drug cleared by state authorities; govt says not approved
Aveo also claimed it is not the only company in India manufacturing a similar combination product. A recent BBC investigation report alleged that the "unlicensed addictive" combination was being illegally exported to African nations such as Ghana and Nigeria, leading to a serious public health crisis of opioid addiction.
from Healthcare/Biotech-Industry-Economic...
KKR to buy cancer care hospital chain HCG from CVC for $400 million
KKR acquires a controlling stake in Healthcare Global from CVC Capital Partners for Rs 3466 crore, strengthening its presence in the healthcare sector. The deal gives KKR up to 77% ownership, and Dr. BS Ajaikumar will take on a new role as Non-Executive Chairman.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FA3rGdI
via IFT...
FDA issues show cause notice to pharma firm in Palghar for illegal export of opioids
Palghar's Food and Drug Administration took legal action against Aveo Pharmaceuticals for alleged illegal opioid export after a BBC report revealed Tapentadol and Carisoprodol were being exported to Africa for recreational use. Authorities raided the company, seized stock, stopped production, and issued a show cause notice, following the Central government's...
India bans production of two drugs ‘behind’ opioid crisis in West Africa
The Drug Controller General of India has banned the production of tapentadol and carisoprodol after they were found to be illegally exported to African nations. These drugs, produced by Aveo Pharma, have contributed to the opioid addiction crisis in countries like Nigeria and Ghana.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uow3dQy
via...
Govt steps up inspections at pharma units to ensure quality
Government authorities have conducted risk-based inspections at over 500 pharmaceutical manufacturing units since 2022 to enhance the quality of locally produced medicines and prevent the sale of spurious drugs. Over 400 actions have been taken against units failing to meet quality standards, and inspections are expected to continue.
from Healthcare/Biotech-Industry-Economic...
Dr Agarwal's Eye Hospital appoints Sachin Tendulkar as its brand ambassador
Dr Agarwal's Eye Hospital has appointed cricket legend Sachin Tendulkar as its brand ambassador. The hospital has been conducting 100 free eye surgeries annually as a tribute to Tendulkar's 100 centuries, and Tendulkar will now help promote awareness about eye care through this collaboration.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q1GLXEW
via...
Apollo Hospitals calls for liberal visa policy to boost medical tourism
Apollo Hospitals' Joint Managing Director Sangita Reddy highlights the need for a liberal visa policy to boost India's medical tourism sector, emphasizing the government's 'Heal in India' initiative. The healthcare provider plans to add around 3,000 beds and invest nearly Rs 6,000 crore for expansion over five years.
from Healthcare/Biotech-Industry-Economic...
Indian drugmakers can retain US dominance even with tariffs, says industry body
Indian pharmaceutical companies are expected to maintain their strong presence in the U.S. generic drug market despite possible high tariffs from President Donald Trump. The Pharmaceuticals Export Promotion Council of India believes these companies' competitiveness will help them navigate the new environment, although higher tariffs may squeeze the...
Pfizer board approves marketing, supply pact with Mylan for two brands
Pfizer Ltd's board has approved a five-year marketing and supply agreement with Mylan Pharmaceuticals for the brands Ativan and Pacitane, targeting the treatment of anxiety disorders and Parkinsonism. The partnership leverages Mylan's expertise in the central nervous system therapy area to enhance product distribution and engagement with neurologists...
India, the 'pharmacy of the world' banks on bilateral talks for relief from planned US tariffs
Indian drugmakers are seeking bilateral discussions with the U.S. to avoid President Donald Trump’s proposed 25% tariff on pharmaceutical imports, according to the Indian Pharmaceutical Alliance (IPA). The U.S. is India's largest market, accounting for $8.7 billion (31%) of total pharma exports in fiscal 2024.
from Healthcare/Biotech-Industry-Economic...
India becoming an attractive option for global pharmaceutical supply chain: Macquarie Report
India's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulatory support. The industry's growth could reach a high-teens CAGR due to factors like the US Biosecure Act, potentially pushing it to USD 22 billion by 2030.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J4TldtY
via...
Not scared of Trump's threats? India's drug, auto exporters see limited impact of US tariffs
Indian exporters believe that US President Trump's proposed tariffs on automobile and pharmaceutical imports will not significantly affect their competitiveness. Industry leaders suggest adjusting domestic policies to mitigate any potential impact. Indian pharmaceuticals and auto components are expected to remain resilient despite the potential for...
Generic pain, margin loss: Drug companies may find it hard to adjust with Trump's tariff plans
US President Trump's 25% tariff plan on pharmaceuticals jeopardizes Indian pharma exports, making generics pricier and impacting margins. Indian companies and stock markets brace for the impact, as India dominates with 30% of exports to the US. Firms may face challenges balancing costs and profit margins.
from Healthcare/Biotech-Industry-Economic...
Tata Group to invest Rs 500 crore in Breach Candy Hospital Expansion
Tata Group will invest Rs 500 crore in Breach Candy Hospital, becoming its largest financial backer. This will allow Tata Group to add three representatives to the board and support infrastructure and technology improvements. Chairman N Chandrasekaran will replace Deepak Parekh as chairman of Breach Candy Hospital Trust from October 2025, while Parekh...
Pharma market in good health; lifestyle diseases may be rising
The other leading molecules in the same segment, like rosuvastatin and telmisartan, continued to grow in line with the therapy segment, the data showed. According to Pharmarack, emerging molecules like vericiguat, finerenone and midodrine also posted robust growth.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vsrhiJD
via IFT...
Practo appoints Jagnoor Singh as COO
Practo has appointed Jagnoor Singh as its new COO to boost growth and refine processes. With 16 years of experience at top firms, Singh will collaborate with CEO Shashank ND to expand into new markets and enhance existing ones, aiming to make healthcare more accessible and affordable.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9PF1sY0
via...
SMT appoints Bhargav Kotadia as chief executive officer
Samara Capital-backed Sahajanand Medical Technologies has named Bhargav Kotadia as CEO and Jose Calle Gordo (‘Pepe’) as chairman, effective April 1. Kotadia replaces Ganesh Sabat, while founder Dhirajlal Kotadia becomes chairman emeritus. The new leadership aims to drive SMT’s growth in cardiovascular technologies, focusing on delivering high-quality...
Glenmark, FDC recall products in US due to manufacturing issues: USFDA
Glenmark Pharmaceuticals and FDC Ltd are recalling some products in the US market. Glenmark is recalling certain strengths of Carvedilol tablets due to impurity issues. FDC Ltd is recalling bottles of glaucoma medication Timolol Maleate due to defective containers. Both recalls were initiated in January 2025 to ensure safety.
from Healthcare/Biotech-Industry-Economic...
Aurobindo Pharma to commence supplies to Europe from China plant in April
Aurobindo Pharma will start supplying products from its new China facility to Europe by April 2024. The company is ramping up production after receiving European regulatory approvals. Plans to enter the US market are also in progress. Aurobindo expects significant revenue growth from this facility over the next two to three years.
from Healthcare/Biotech-Industry-Economic...
MSD Pharma, Delhi Capitals partner to create awareness about cervical cancer prevention
MSD Pharmaceuticals and Delhi Capitals have partnered to raise cervical cancer prevention awareness in India. The women's T20 team will display this message on their jerseys during matches. The initiative aims to reduce stigma, provide information accessibility, and promote preventive health measures. Cervical cancer remains a major issue in India...
'Discover and Make in India' to drive innovation in pharma, says Dilip Shanghvi, Founder & Managing Director, Sun Pharmaceutical Industries
India has established itself as a global leader in pharmaceutical production, with potential for further growth through increased investment in drug discovery. Companies like Sun Pharma are already making strides with innovative products and clinical trials, promising a future where India can contribute significantly to global healthcare.
from Healthcare/Biotech-Industry-Economic...
Zydus Lifesciences inks licensing pact with Zhuhai for cancer drug
Zydus Lifesciences' subsidiary partners with Zhuhai Beihai Biotech to market Beizray, a cancer drug, in the US. Zhuhai will handle manufacturing while Zydus will commercialize the product, targeting breast cancer and other types. The partnership includes milestone payments and profit-sharing, tapping into a market of around 531,000 units annually.
from...
Glenmark launches generic ophthalmic solution in US market
Glenmark Pharmaceuticals' subsidiary has introduced Latanoprost ophthalmic solution, a generic medication for glaucoma, in the US market. The product matches Upjohn US LLC's Xalatan Ophthalmic Solution, which had annual sales of USD 113.5 million. This launch reflects Glenmark's growing ophthalmic portfolio and commitment to quality solutions.
from...
KKR set to buy cancer chain HCG
KKR is set to acquire a 51% stake in Healthcare Global Enterprises from CVC Capital Partners. The $3,128 crore deal includes an open offer for an additional 26%. HCG's founding family will retain 10.87%, while the company's growth trajectory and expanded capabilities are expected post-acquisition.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PjabrcN
via...
India, Indonesia ink milestone pact for quality assurance in traditional medicine: Ayush Minister
The Union Minister of State (Independent Charge), Ministry of Ayush, Prataprao Jadhav, stated that the MoU exchanged between India and Indonesia in the field of traditional medicine quality assurance between Pharmacopoeia Commission for Indian Medicine & Homeopathy, Ministry of Ayush and Indonesian Food and Drug Authority.
from Healthcare/Biotech-Industry-Economic...
Pharma companies must file compliance strategy
Drugmakers must complete a gap analysis and submit their compliance strategy to extend Schedule M implementation. Small and medium manufacturers, with a turnover of less than ₹250 crore, have until December 31 to comply. They need to submit their upgrade plans within three months.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y3BVLIr
via...
Zydus Lifesciences in pact with Synthon for specialty oncology product in US
Zydus Lifesciences has signed an exclusive agreement with Synthon for the development and commercialisation of a novel oncology product, focusing on reducing pill burden and improving patient compliance. Synthon will handle development and manufacturing, while Zydus will oversee NDA submission and marketing in the US by 2026.
from Healthcare/Biotech-Industry-Economic...
Govt extends Schedule M implementation deadline till year-end for small, medium pharma firms
The implementation of revised Schedule M for good manufacturing practices has been conditionally extended to December 31, 2025, for small and medium pharmaceutical firms with turnover of Rs 250 crore or less. These firms must submit an upgrade plan by February 11, 2025, to qualify for the deadline extension. The updated regulations aim to enhance product...
Biovet's new vax developed to treat skin disease of livestock gets regulator's license
Biovet has secured a license from CDSCO for Biolumpivaxin, the world's only marker vaccine for Lumpy Skin Disease in cattle and buffaloes. Developed with the DIVA concept, it ensures high safety and efficacy while distinguishing between infected and vaccinated animals, a crucial step toward India's self-reliance in veterinary healthcare.
from Healthcare/Biotech-Industry-Economic...
Over 3k brands hit pharma mkt, cancer drug tops in sales
India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the top-seller, reflecting a rise in cancer cases. Enhertu, exempted from customs duty, has significantly contributed to AstraZeneca's sales, highlighting the growing demand for innovative cancer treatments.
from Healthcare/Biotech-Industry-Economic...
Biocon betting big on new product launches for growth
Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This strategy integrates development, production, distribution, and market deployment. Biocon Biologics has acquired Viatris' global biosimilars business, boosting revenue. The company is building a strong brand presence globally, especially...
Bajaj dynasty said to earmark Rs 10,000 crore for hospital chain
Bajaj Group earmarks 100 billion rupees ($1.1 billion) to establish a chain of affordable, high-class hospitals across India. This move aligns with the nation's growing healthcare needs and increased insurance coverage. Led by Nirav Bajaj, this initiative marks the conglomerate's new venture amid its diversified portfolio, including Bajaj Auto and...
India's Pharma market to expand 2.4 times over next 5 years, share in global market to hit 5 pc: Report
India's pharmaceutical industry is set to grow significantly, with its share in the global market expected to reach 5% by 2030. Currently valued at USD 55 billion, the market is projected to hit up to USD 130 billion, driven by strong domestic demand and increasing global exports.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0zHfUdq
via...
NPPA asks retailers to display drug prices on websites
The National Pharmaceutical Pricing Authority (NPPA) will take action if the pharmacies fail to comply with the diktat, it said in an order. It may be noted that the online pharmacies and other online platforms selling medicines were not displaying the prices of drugs, firmly refusing to do so citing extract from the Para 24 of the Drugs (Price Control)...
Sanofi Healthcare gets marketing authorisation for cGVHD drug
Sanofi Healthcare India has obtained marketing authorization for Rezurock, a drug for treating Chronic graft versus host disease (cGVHD), a condition that occurs after allogeneic stem cell transplants. The drug, approved by USFDA and CDSCO, offers a new treatment option for patients over 12 years old after other treatments have failed.
from Healthcare/Biotech-Industry-Economic...
Glenmark, Cosmo get MHRA nod for acne treatment medication
Glenmark Pharmaceuticals and Cosmo Pharmaceuticals have received MHRA approval to market Winlevi, a topical acne treatment for patients aged 12 and older in the UK. Glenmark licensed the product from Cosmo for distribution in Europe and South Africa, aiming to improve the quality of life for those suffering from acne, which affects a significant portion...
Rashmi Saluja's re-appointment to REL board fails to get shareholders' stamp
Rashmi Saluja's reappointment to Religare Enterprises' board was overwhelmingly rejected by shareholders, with 97.53% voting against it. Despite Saluja's refusal to step down, the resolution was blocked, and the Delhi High Court affirmed that executive directors must retire by rotation as per the Companies Act.
from Healthcare/Biotech-Industry-Economic...
India's CDMO market set to double by 2028 amid Asia's healthcare boom
India's CDMO market is set to grow from USD 7 billion to USD 14 billion by 2028. This growth is driven by its strong stance in API manufacturing and cost advantages over China. Global pharmaceutical companies are diversifying supply chains to India. The broader APAC healthcare sector is also expanding rapidly, supported by rising income levels.
from...
Pharma exports expected to double to $65 billion by 2030: Report
India's pharmaceutical exports are set to reach USD 65 billion by 2030 and USD 350 billion by 2047, placing India among the top five global exporters by diversifying its product range. The report highlights the need for innovation, quality focus, and collaboration between the government and private sector to achieve this growth, emphasizing specialty...
What are nutraceuticals and why are they gaining popularity in India
Nutraceuticals in India are gaining popularity due to rising health awareness, an increase in lifestyle diseases, and a shift toward natural products. The market is expected to grow significantly, driven by government initiatives, increased disposable incomes, and the expansion of online retail models.
from Healthcare/Biotech-Industry-Economic Times...
Alkem Labs acquires two companies specialising in skin care, medtech to bolster domestic business
Alkem Laboratories has announced two strategic acquisitions totaling Rs 287 crores to strengthen its domestic market presence. The company will acquire Adroit Biomed for Rs 140 crore and Bombay Ortho Industries for Rs 147 crore. These acquisitions will diversify Alkem's portfolio and meet growing market demands.
from Healthcare/Biotech-Industry-Economic...
IHH Healthcare seeks damages of upto Rs 10,930 cr from Daiichi Sankyo for obstructing open offer for Fortis
IHH Healthcare is seeking up to Rs 10,930 crore in damages from Daiichi Sankyo for allegedly obstructing NTK's acquisition of Fortis Healthcare. IHH announced that NTK has submitted an additional claim with an expert report to quantify the damages. The dispute stems from a 2018 open offer block by Daiichi's contempt plea against Fortis founders.
from...
Dr Reddy's unit ties up with Shanghai Henlius Biotech
Dr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the cancer drug Darzalex. Henlius will manage development and manufacturing, receiving up to $131.6 million. Dr Reddy's gains exclusive rights to market the drug in the US and Europe.
from Healthcare/Biotech-Industry-Economic Times...
GBS patient treated in Gurugram, cases rise in Pune
Healthcare authorities are closely monitoring the outbreak of Guillain-Barre Syndrome (GBS) in Pune as cases rise to 158, with five deaths suspected in Maharashtra. Doctors report instances of muscle weakness and dysfunction, primarily affecting the younger population, and are coordinating efforts with the Centre to control the spread.
from Healthcare/Biotech-Industry-Economic...
ICMR initiates process of vaccine against avian influenza
The ICMR has launched efforts to develop a human vaccine against the highly-pathogenic avian influenza H5N1. This virus poses a significant public health risk due to its high mortality rate and potential to cause global pandemic. Recent outbreaks highlight the urgency of vaccine development for better preparedness.
from Healthcare/Biotech-Industry-Economic...